Shared on04 Aug 25Fair value Decreased 17%
The consensus analyst price target for Twist Bioscience has been revised downward as a result of a notable decrease in its future P/E ratio, partially offset by an improvement in net profit margin, bringing the fair value estimate down from $48.42 to $44.72. What's in the News Launched a humanized transgenic (HuTg) mouse model to enhance antibody discovery services, allowing customers to identify fully human hits in weeks and complementing existing in vivo capabilities.
Shared on24 Apr 25Fair value Decreased 1.41%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 2.25%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.
Shared on09 Apr 25Fair value Decreased 3.16%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 3.44%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 14%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.